Call Options

14 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q1 2024

May 15, 2024

SELL
$47.98 - $54.4 $15.9 Million - $18 Million
-331,300 Reduced 86.89%
50,000 $2.71 Million
Q4 2023

Feb 14, 2024

SELL
$48.48 - $57.85 $17 Million - $20.2 Million
-350,000 Reduced 47.86%
381,300 $19.6 Million
Q2 2023

Aug 14, 2023

BUY
$63.71 - $70.74 $38.2 Million - $42.4 Million
600,000 Added 456.97%
731,300 $46.8 Million
Q1 2023

May 15, 2023

BUY
$65.71 - $74.53 $8.63 Million - $9.79 Million
131,300 New
131,300 $9.1 Million
Q3 2022

Nov 14, 2022

SELL
$0.13 - $76.84 $50,700 - $30 Million
-390,000 Reduced 43.82%
500,000 $35.5 Million
Q2 2022

Aug 15, 2022

BUY
$72.62 - $79.98 $64 Million - $70.5 Million
881,000 Added 9788.89%
890,000 $68.5 Million
Q4 2021

Feb 14, 2022

SELL
$53.63 - $62.52 $3.7 Million - $4.31 Million
-69,000 Reduced 88.46%
9,000 $561,000
Q3 2021

Nov 15, 2021

BUY
$59.17 - $69.31 $520,696 - $609,928
8,800 Added 12.72%
78,000 $4.62 Million
Q2 2020

Aug 14, 2020

SELL
$54.82 - $64.09 $8.43 Million - $9.85 Million
-153,700 Reduced 68.95%
69,200 $4.07 Million
Q1 2020

May 14, 2020

BUY
$46.4 - $67.43 $1.53 Million - $2.22 Million
32,900 Added 17.32%
222,900 $12.4 Million
Q4 2019

Feb 13, 2020

SELL
$49.21 - $64.19 $12.7 Million - $16.5 Million
-257,500 Reduced 57.54%
190,000 $12.2 Million
Q3 2019

Nov 13, 2019

SELL
$42.77 - $50.71 $12.9 Million - $15.3 Million
-302,600 Reduced 40.34%
447,500 $22.7 Million
Q3 2018

Nov 13, 2018

BUY
$55.19 - $62.25 $37.1 Million - $41.9 Million
672,600 Added 867.87%
750,100 $46.6 Million
Q3 2017

Nov 13, 2017

BUY
$55.23 - $63.74 $4.28 Million - $4.94 Million
77,500
77,500 $4.94 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $123B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Laurion Capital Management LP Portfolio

Follow Laurion Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Laurion Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Laurion Capital Management LP with notifications on news.